Treatments
Source: OpenFDA drug label API · last checked
Monoclonal antibodies and antibody-drug conjugates (ADCs) that bind specific proteins on cancer cells.
CD52-directed Cytolytic Antibody [EPC] · CD52-directed Antibody Interactions [MoA]
From the FDA label: 1 INDICATIONS AND USAGE CAMPATH is indicated as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL). CAMPATH is a CD52-directed cytolytic antibody indicated as a single agent for the treatment of B-cell chronic l…
CD33-directed Immunoconjugate [EPC] · CD33-directed Antibody Interactions [MoA]
From the FDA label: 1 INDICATIONS AND USAGE MYLOTARG is a CD33-directed antibody and cytotoxic drug conjugate indicated for: • treatment of newly-diagnosed CD33-positive acute myeloid leukemia (AML) in adults and pediatric patients 1 month and older ( 1.1 ). •…
CD22-directed Immunoconjugate [EPC] · CD22-directed Antibody Interactions [MoA]
From the FDA label: 1. INDICATIONS AND USAGE BESPONSA is indicated for the treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients 1 year and older . BESPONSA is a CD22-directed anti…
CD20-directed Cytolytic Antibody [EPC] · CD20-directed Antibody Interactions [MoA]
From the FDA label: 1 INDICATIONS AND USAGE GAZYVA is a CD20-directed cytolytic antibody indicated: in combination with chlorambucil, for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL). ( 1.1 , 14 ) in combination with b…
CD20-directed Cytolytic Antibody [EPC] · CD20-directed Antibody Interactions [MoA]
From the FDA label: 1 INDICATIONS AND USAGE RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of: Adult patients with Non-Hodgkin's Lymphoma (NHL) ( 1.1 ). Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a s…
CD20-directed Cytolytic Antibody [EPC] · Endoglycosidase [EPC]
From the FDA label: 1 INDICATIONS AND USAGE RITUXAN HYCELA is a combination of rituximab, a CD20-directed cytolytic antibody, and hyaluronidase human, an endoglycosidase, indicated for the treatment of adult patients with: Follicular Lymphoma (FL) ( 1.1 ) Rela…
CD20-directed Cytolytic Antibody [EPC] · CD20-directed Antibody Interactions [MoA]
From the FDA label: 1 INDICATIONS AND USAGE TRUXIMA (rituximab-abbs) is a CD20-directed cytolytic antibody indicated for the treatment of adult patients with: Non-Hodgkin's Lymphoma (NHL) ( 1.1 ). Relapsed or refractory, low grade or follicular, CD20-positive
CD20-directed Cytolytic Antibody [EPC] · CD20-directed Antibody Interactions [MoA]
From the FDA label: 1 INDICATIONS AND USAGE RIABNI is a CD20-directed cytolytic antibody indicated for the treatment of: Adult patients with Non-Hodgkin's Lymphoma (NHL) ( 1.1 ). Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a si…
CD20-directed Cytolytic Antibody [EPC] · CD20-directed Antibody Interactions [MoA]
From the FDA label: 1 INDICATIONS AND USAGE RUXIENCE is a CD20-directed cytolytic antibody indicated for the treatment of: • Adult patients with Non-Hodgkin's Lymphoma (NHL) ( 1.1 ). o Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL a…
Small-molecule drugs taken by mouth that block specific molecular pathways driving cancer growth (kinases, PARP, CDK4/6, etc.).
Nucleoside Metabolic Inhibitor [EPC] · Anthracycline Topoisomerase Inhibitor [EPC]
From the FDA label: 1 INDICATIONS AND USAGE VYXEOS is indicated for the treatment of newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older. VYXEOS i…
Kinase Inhibitor [EPC] · Tyrosine Kinase Inhibitors [MoA]
From the FDA label: 1 INDICATIONS AND USAGE CALQUENCE is a kinase inhibitor indicated: • In combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous h…
From the FDA label: 1 INDICATIONS AND USAGE SCEMBLIX is indicated for the treatment of adult patients with: Newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP). This indication is approved under accelerated…
From the FDA label: 1 INDICATIONS AND USAGE Dasatinib tablets are indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. chronic, accelerated, or myeloid or lym…
From the FDA label: 1 INDICATIONS AND USAGE COPIKTRA is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior lines of systemic therapy. Limitat…
From the FDA label: 1 INDICATIONS AND USAGE XOSPATA is a kinase inhibitor indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test. ( 1.1 ) 1.1 Relapsed
Kinase Inhibitor [EPC] · Protein Kinase Inhibitors [MoA]
From the FDA label: 1 INDICATIONS AND USAGE IMBRUVICA is a kinase inhibitor indicated for the treatment of: Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) ( 1.1 ). Adult patients with chronic lymphocytic leukemia (CLL)/…
Kinase Inhibitor [EPC] · Kinase Inhibitors [MoA]
From the FDA label: 1 INDICATIONS AND USAGE Zydelig is indicated, in combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL) for whom rituximab alone would be considered appropriate therapy due to other co-mor…
From the FDA label: 1 INDICATIONS AND USAGE Imatinib mesylate tablets are a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.…
From the FDA label: 1 INDICATIONS AND USAGE Imatinib mesylate is a kinase inhibitor indicated for the treatment of: • Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase ( 1.1 )…
From the FDA label: 1 INDICATIONS AND USAGE Imkeldi is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. ( 1.1 ) Patients w…
Isocitrate Dehydrogenase 1 Inhibitor [EPC] · Isocitrate Dehydrogenase 1 Inhibitors [MoA]
From the FDA label: 1 INDICATIONS AND USAGE TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with: Newly Diagnosed Acute Myeloid Leukemia (AML) In combination
Kinase Inhibitor [EPC] · Bcr-Abl Tyrosine Kinase Inhibitors [MoA]
From the FDA label: 1 INDICATIONS AND USAGE Nilotinib capsules are a kinase inhibitor indicated for the treatment of: Adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leuk…
From the FDA label: 1 INDICATIONS AND USAGE Relapsed or Refractory Acute Myeloid Leukemia REZLIDHIA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) m…
Kinase Inhibitor [EPC] · Bruton's Tyrosine Kinase Inhibitors [MoA]
From the FDA label: 1 INDICATIONS AND USAGE JAYPIRCA ® is a kinase inhibitor indicated for the treatment of: Adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor. ( 1.1 ).…
From the FDA label: 1 INDICATIONS AND USAGE ICLUSIG ® is indicated for the treatment of adult patients with: Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Newly diagnosed Ph+ ALL in combination with chemotherapy. This indication is ap…
From the FDA label: 1 INDICATIONS AND USAGE VANFLYTA is indicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult
From the FDA label: 1 INDICATIONS AND USAGE REVUFORJ is a menin inhibitor indicated for: the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene ( KMT2A ) translocation as determined by an FDA-authorized test in adult and…
Kinase Inhibitor [EPC] · Receptor Tyrosine Kinase Inhibitors [MoA]
From the FDA label: 1 INDICATIONS AND USAGE RYDAPT is a kinase inhibitor indicated for the treatment of adult patients with: Newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive as detected by an FDA-approved test, in combination with st…
Kinase Inhibitor [EPC] · Bruton's Tyrosine Kinase Inhibitors [MoA]
From the FDA label: 1 INDICATIONS AND USAGE BRUKINSA is a kinase inhibitor indicated for the treatment of adult patients with: Mantle cell lymphoma (MCL) who have received at least one prior therapy. ( 1.1 ) This indication is approved under accelerated approv…
Menin Inhibitor [EPC] · Menin Inhibitors [MoA]
From the FDA label: 1 INDICATIONS AND USAGE KOMZIFTI is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 ( NPM1 ) mutation who have no satisfactory alternative treatment o…
Therapies using genetically modified or harvested cells — CAR-T, TIL therapy, and related cellular treatments.
From the FDA label: 1 INDICATIONS AND USAGE TECARTUS is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of: Adult patients with relapsed or refractory mantle cell lymphoma (MCL). Adult patients with relapsed or
From the FDA label: 1 INDICATIONS AND USAGE BREYANZI is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of: • adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not…
From the FDA label: 1 INDICATION AND USAGE AUCATZYL is indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). AUCATZYL is a CD19-directed genetically modified autologous T cell immunotherapy indic…
CD19-directed Chimeric Antigen Receptor [EPC] · Genetically-modified Autologous T Cells [EPC]
From the FDA label: 1 INDICATIONS AND USAGE KYMRIAH is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of: Patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refracto…
Cytotoxic drugs that kill rapidly dividing cells. Includes platinums, taxanes, antimetabolites, alkylators, topoisomerase inhibitors, and anthracyclines.
From the FDA label: 1 INDICATIONS AND USAGE Bendamustine Hydrochloride for Injection is an alkylating drug indicated for treatment of patients with: Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not b…
From the FDA label: 1 INDICATIONS AND USAGE Bendamustine hydrochloride for Injection is an alkylating drug indicated for treatment of patients with: Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not b…
From the FDA label: 1 INDICATIONS AND USAGE Cyclophosphamide for injection is an alkylating drug indicated for treatment of adults and pediatric patients with: Malignant Diseases: malignant lymphomas: Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type ly…
From the FDA label: 1 INDICATIONS AND USAGE Cyclophosphamide for Injection is an alkylating drug indicated for treatment of adults and pediatric patients with: • Malignant Diseases: malignant lymphomas: Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type
From the FDA label: 1 INDICATIONS AND USAGE Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult and pediatric patients with: • malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphoc…
From the FDA label: 1 INDICATIONS AND USAGE Doxorubicin hydrochloride for injection is an anthracycline topoisomerase inhibitor indicated: as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following
From the FDA label: 1 INDICATIONS AND USAGE Doxorubicin Hydrochloride Injection is an anthracycline topoisomerase inhibitor indicated: • as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following r…
Antimetabolite [EPC] · Urea [CS]
From the FDA label: 1 INDICATIONS AND USAGE Hydroxyurea capsules, USP is indicated for the treatment of: Resistant chronic myeloid leukemia. Locally advanced squamous cell carcinomas of the head and neck (excluding the lip) in combination with chemoradiation.
From the FDA label: 1 INDICATIONS AND USAGE IDAMYCIN PFS is indicated for the treatment of adult patients with acute myeloid leukemia (AML) as a component of a combination chemotherapy regimen. IDAMYCIN PFS is an anthracycline topoisomerase inhibitor indicated…
From the FDA label: 1 INDICATIONS AND USAGE Methotrexate tablets are a diydrofolate reductase inhibitor indicated for the: • Treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance re…
From the FDA label: 1 INDICATIONS AND USAGE Methotrexate Tablets are a diydrofolate reductase inhibitor indicated for the: • Treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance re…
Drugs whose pharmacologic class was not automatically classified into the groups above. Check the FDA label for mechanism details.
Asparagine-specific Enzyme [EPC] · Asparaginase [CS]
From the FDA label: 1 INDICATIONS AND USAGE RYLAZE is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older w…
Nucleoside Metabolic Inhibitor [EPC] · Nucleic Acid Synthesis Inhibitors [MoA]
From the FDA label: 1 INDICATIONS AND USAGE ONUREG is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensiv…
From the FDA label: 1 INDICATIONS AND USAGE BLINCYTO is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of adult and pediatric patients one month and older with: CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in fir…
Asparagine-specific Enzyme [EPC] · Asparaginase [CS]
From the FDA label: 1 INDICATIONS AND USAGE ASPARLAS is an asparagine specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 month to 21 y…
Nucleoside Metabolic Inhibitor [EPC] · Nucleic Acid Synthesis Inhibitors [MoA]
From the FDA label: 1 INDICATIONS AND USAGE Clofarabine injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens. Clofarabine injection is a nucl…
From the FDA label: 1 INDICATIONS AND USAGE IDHIFA is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected
Leukocyte Growth Factor [EPC] · Granulocyte Colony-Stimulating Factor [CS]
From the FDA label: 1 INDICATIONS AND USAGE RELEUKO is a leukocyte growth factor indicated to: Decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti- cancer drugs ass…
Leukocyte Growth Factor [EPC] · Granulocyte Colony-Stimulating Factor [CS]
From the FDA label: 1 INDICATIONS AND USAGE NIVESTYM is a leukocyte growth factor indicated to • Decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs as…
Leukocyte Growth Factor [EPC] · Granulocyte Colony-Stimulating Factor [CS]
From the FDA label: 1 INDICATIONS AND USAGE ZARXIO is a leukocyte growth factor indicated to • Decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti‑cancer drugs asso…
Leukocyte Growth Factor [EPC] · Granulocyte Colony-Stimulating Factor [CS]
From the FDA label: 1 INDICATIONS AND USAGE NYPOZI is a leukocyte growth factor indicated to: Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs assoc…
From the FDA label: 1 INDICATIONS AND USAGE Fludarabine Phosphate Injection is a nucleotide metabolic inhibitor indicated for: The treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progres…
Hedgehog Pathway Inhibitor [EPC] · Smoothened Receptor Antagonists [MoA]
From the FDA label: 1 INDICATIONS AND USAGE DAURISMO is indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are ≥75 years old or who have comorbidities that preclude use of…
Thalidomide Analog [EPC]
From the FDA label: 1 INDICATIONS AND USAGE Lenalidomide is a thalidomide analogue indicated for the treatment of adult patients with: Multiple myeloma (MM), in combination with dexamethasone ( 1.1 ). Transfusion-dependent anemia due to low- or intermediate-1-…
From the FDA label: 1 INDICATIONS AND USAGE Mercaptopurine is a nucleoside metabolic inhibitor indicated for the treatment of patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen. ( 1.1 ) 1.1 Acute Lymphobl…
Nucleoside Metabolic Inhibitor [EPC] · Nucleic Acid Synthesis Inhibitors [MoA]
From the FDA label: 1 INDICATIONS AND USAGE Nelarabine injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not
Asparagine-specific Enzyme [EPC] · Asparaginase [CS]
From the FDA label: 1 INDICATIONS AND USAGE ONCASPAR is an asparagine specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for treatment of pediatric and adult patients with: First-line acute lymphoblastic leukemia ( 1.1 ) Acute l…
From the FDA label: 1 INDICATIONS AND USAGE PURIXAN is a nucleoside metabolic inhibitor indicated for the treatment of patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.( 1.1 ) 1.1 Acute Lymphoblastic Le…
Leukocyte Growth Factor [EPC] · Granulocyte Colony-Stimulating Factor [CS]
From the FDA label: 1 INDICATIONS AND USAGE LEUKINE is a leukocyte growth factor indicated: To shorten time to neutrophil recovery and to reduce the incidence of severe and life-threatening infections and infections resulting in death following induction chemo…
From the FDA label: INDICATIONS AND USAGE a) Acute Nonlymphocytic Leukemias TABLOID brand Thioguanine is indicated for remission induction and remission consolidation treatment of acute nonlymphocytic leukemias. However, it is not recommended for use during ma…
From the FDA label: 1 INDICATIONS AND USAGE GRAFAPEX is an alkylating drug indicated for: Use in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation (alloHSCT) in adult and pediatric patients 1 year of a…
BCL-2 Inhibitor [EPC] · P-Glycoprotein Inhibitors [MoA]
From the FDA label: 1 INDICATIONS AND USAGE VENCLEXTA is a BCL-2 inhibitor indicated: For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ( 1.1 ) In combination with azacitidine, or decitabine, or lo…
Disease foundations below have active funds covering leukemia medications. Manufacturer patient-assistance programs are listed on each drug's cost page.
copay, premium, and deductible assistance for insured patients; fund availability varies by disease
https://www.healthwellfoundation.org/disease-funds/Funds open and close based on availability; check disease-funds page for current status
copay assistance for 20+ cancer types via disease-specific funds
https://www.panfoundation.org/find-disease-fund/Merging with Patient Advocate Foundation; unified 'TotalAssist' program launches 2026-07-01
direct copay / coinsurance assistance via disease-specific funds
https://copays.org/Merging with PAN Foundation; launching 'TotalAssist' 2026-07-01
copay assistance for chemotherapy and targeted treatment medications
https://www.cancercare.org/copayfoundationlimited financial assistance for transportation, home care, child care, and treatment-related costs
https://www.cancercare.org/financialTrials test new therapies before they are FDA-approved. Often a way to access tomorrow's drugs today.
Back to Leukemia hub →Stats, second opinions, NCI cancer centers, oncologists.
Understand biomarkers →Most targeted therapies require biomarker testing. Here's what you need to know.
Read your pathology report →Which drugs apply to you depends on what's in your pathology.